<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342392</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT02342392</nct_id>
  </id_info>
  <brief_title>Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study</brief_title>
  <official_title>Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Science Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Science Malaysia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pterygium vascularity and size before and after
      intralesional ranibizumab injection and to evaluate its recurrence rate following pterygium
      excision surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to:

        1. Compare the vascularity of primary pterygium before and 1 week after intralesional
           ranibizumab (0.3 mg/0.03 mL) injection.

        2. Compare the size of primary pterygium before and 1 week after intralesional ranibizumab
           (0.3 mg/0.03 mL) injection.

        3. Compare the recurrence rate at 1 year after pterygium excision surgery between the group
           with and without intralesional ranibizumab injection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pterygium recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>pterygium recurrence is defined as true recurrence with a fibrovascular tissue invading the cornea (grade 4 lesion)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pterygium vessel area</measure>
    <time_frame>1 week</time_frame>
    <description>Pterygium vesel area is defined as the as the ration of pixels occupied by the vessels within the pterygium area in percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>corneal pterygium area</measure>
    <time_frame>1 week</time_frame>
    <description>Corneal pterygium area is defined as the as the ration of pixels occupied by the pterygium within the cornea area in percentage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pterygium</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intralesional ranibizumab injected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intralesional ranibizumab injected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.</description>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with primary pterygium.

          -  Grade T3 (fleshy) pterygium.

        Exclusion Criteria:

          -  Patients with other ocular surface disorders.

          -  Previous ocular surgery or trauma.

          -  History of systemic thromboembolic event.

          -  Pregnant women and lactating mother.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hao Chi Ho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universiti Sains Malaysia</affiliation>
  </overall_official>
  <reference>
    <citation>Lee DH, Cho HJ, Kim JT, Choi JS, Joo CK. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea. 2001 Oct;20(7):738-42.</citation>
    <PMID>11588427</PMID>
  </reference>
  <reference>
    <citation>Blaudschun R, Sunderkötter C, Brenneisen P, Hinrichs R, Peters T, Schneider L, Razi-Wolf Z, Hunzelmann N, Scharffetter-Kochanek K. Vascular endothelial growth factor causally contributes to the angiogenic response upon ultraviolet B irradiation in vivo. Br J Dermatol. 2002 Apr;146(4):581-7.</citation>
    <PMID>11966687</PMID>
  </reference>
  <reference>
    <citation>Di Girolamo N, Chui J, Coroneo MT, Wakefield D. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res. 2004 Mar;23(2):195-228. Review.</citation>
    <PMID>15094131</PMID>
  </reference>
  <reference>
    <citation>Tan DT, Lim AS, Goh HS, Smith DR. Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium. Am J Ophthalmol. 1997 Mar;123(3):404-5.</citation>
    <PMID>9063255</PMID>
  </reference>
  <reference>
    <citation>Tan DT, Chee SP, Dear KB, Lim AS. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol. 1997 Oct;115(10):1235-40. Erratum in: Arch Ophthalmol 1998 Apr;116(4):552.</citation>
    <PMID>9338666</PMID>
  </reference>
  <reference>
    <citation>Prabhasawat P, Barton K, Burkett G, Tseng SC. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology. 1997 Jun;104(6):974-85.</citation>
    <PMID>9186439</PMID>
  </reference>
  <reference>
    <citation>Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol. 2007 Jul;18(4):308-13. Review.</citation>
    <PMID>17568207</PMID>
  </reference>
  <reference>
    <citation>Prabhasawat P, Tesavibul N, Leelapatranura K, Phonjan T. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology. 2006 Jul;113(7):1102-9. Epub 2006 May 26.</citation>
    <PMID>16730066</PMID>
  </reference>
  <reference>
    <citation>Hirst LW, Sebban A, Chant D. Pterygium recurrence time. Ophthalmology. 1994 Apr;101(4):755-8.</citation>
    <PMID>8152771</PMID>
  </reference>
  <reference>
    <citation>Razeghinejad MR, Hosseini H, Ahmadi F, Rahat F, Eghbal H. Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res. 2010;43(3):134-8. doi: 10.1159/000252980. Epub 2009 Oct 29.</citation>
    <PMID>19887878</PMID>
  </reference>
  <reference>
    <citation>Poenaru Sava MG, Raica ML, Cimpean AM. VEGF mRNA assessment in human pterygium: a new 'scope' for a future hope. Ophthalmic Res. 2014;52(3):130-5. doi: 10.1159/000363142. Epub 2014 Oct 3.</citation>
    <PMID>25300614</PMID>
  </reference>
  <reference>
    <citation>Mansour AM. Treatment of inflamed pterygia or residual pterygial bed. Br J Ophthalmol. 2009 Jul;93(7):864-5. doi: 10.1136/bjo.2008.155291.</citation>
    <PMID>19553512</PMID>
  </reference>
  <reference>
    <citation>Teng CC, Patel NN, Jacobson L. Effect of subconjunctival bevacizumab on primary pterygium. Cornea. 2009 May;28(4):468-70. doi: 10.1097/ICO.0b013e31818d382d.</citation>
    <PMID>19411971</PMID>
  </reference>
  <reference>
    <citation>Wu PC, Kuo HK, Tai MH, Shin SJ. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea. 2009 Jan;28(1):103-4. doi: 10.1097/ICO.0b013e3181822615.</citation>
    <PMID>19092418</PMID>
  </reference>
  <results_reference>
    <citation>Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses. 2007;69(4):925-7. Epub 2007 Mar 26.</citation>
    <PMID>17367957</PMID>
  </results_reference>
  <results_reference>
    <citation>Hurmeric V, Vaddavalli P, Galor A, Perez VL, Roman JS, Yoo SH. Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium. Clin Ophthalmol. 2013;7:467-73. doi: 10.2147/OPTH.S40400. Epub 2013 Mar 4.</citation>
    <PMID>23486999</PMID>
  </results_reference>
  <results_reference>
    <citation>Galor A, Yoo SH, Piccoli FV, Schmitt AJ, Chang V, Perez VL. Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. Am J Ophthalmol. 2010 Jun;149(6):926-931.e2. doi: 10.1016/j.ajo.2010.01.015. Epub 2010 Apr 24.</citation>
    <PMID>20417925</PMID>
  </results_reference>
  <results_reference>
    <citation>Mandalos A, Tsakpinis D, Karayannopoulou G, Tsinopoulos I, Karkavelas G, Chalvatzis N, Dimitrakos S. The effect of subconjunctival ranibizumab on primary pterygium: a pilot study. Cornea. 2010 Dec;29(12):1373-9. doi: 10.1097/ICO.0b013e3181d927b9.</citation>
    <PMID>20856107</PMID>
  </results_reference>
  <results_reference>
    <citation>Benayoun Y, Adenis JP, Casse G, Forte R, Robert PY. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study. Cornea. 2012 Aug;31(8):937-44. doi: 10.1097/ICO.0b013e31823f8d71.</citation>
    <PMID>22357391</PMID>
  </results_reference>
  <results_reference>
    <citation>Enkvetchakul O, Thanathanee O, Rangsin R, Lekhanont K, Suwan-Apichon O. A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results. Cornea. 2011 Nov;30(11):1213-8. doi: 10.1097/ICO.0b013e31821c9b44.</citation>
    <PMID>21915047</PMID>
  </results_reference>
  <results_reference>
    <citation>Lekhanont K, Patarakittam T, Thongphiew P, Suwan-apichon O, Hanutsaha P. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Cornea. 2012 Feb;31(2):155-61. doi: 10.1097/ICO.0b013e3182151e0e.</citation>
    <PMID>22081150</PMID>
  </results_reference>
  <results_reference>
    <citation>Razeghinejad MR, Banifatemi M. Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial. J Ophthalmic Vis Res. 2014 Jan;9(1):22-30.</citation>
    <PMID>24982728</PMID>
  </results_reference>
  <results_reference>
    <citation>Razeghinejad R, Banifatemi M, Hosseini H. The effect of different doses of subconjunctival bevacizumab on the recurrence rate of excised primary pterygium. Bull Soc Belge Ophtalmol. 2013;(322):13-20.</citation>
    <PMID>24923077</PMID>
  </results_reference>
  <results_reference>
    <citation>Shenasi A, Mousavi F, Shoa-Ahari S, Rahimi-Ardabili B, Fouladi RF. Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. Cornea. 2011 Nov;30(11):1219-22. doi: 10.1097/ICO.0b013e31820ca63f.</citation>
    <PMID>21955635</PMID>
  </results_reference>
  <results_reference>
    <citation>Shahin MM, Elbendary AM, Elwan MM. Intraoperative subconjunctival bevacizumab as an adjunctive treatment in primary pterygium: a preliminary report. Ophthalmic Surg Lasers Imaging. 2012 Nov-Dec;43(6):459-66. doi: 10.3928/15428877-20120802-02. Epub 2012 Aug 10.</citation>
    <PMID>22882007</PMID>
  </results_reference>
  <results_reference>
    <citation>Ozgurhan EB, Agca A, Kara N, Yuksel K, Demircan A, Demirok A. Topical application of bevacizumab as an adjunct to recurrent pterygium surgery. Cornea. 2013 Jun;32(6):835-8. doi: 10.1097/ICO.0b013e3182772d4e.</citation>
    <PMID>23187164</PMID>
  </results_reference>
  <results_reference>
    <citation>Karalezli A, Kucukerdonmez C, Akova YA, Koktekir BE. Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting? Int J Ophthalmol. 2014 Jun 18;7(3):512-6. doi: 10.3980/j.issn.2222-3959.2014.03.23. eCollection 2014.</citation>
    <PMID>24967201</PMID>
  </results_reference>
  <results_reference>
    <citation>Nava-Castañeda A, Olvera-Morales O, Ramos-Castellon C, Garnica-Hayashi L, Garfias Y. Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1-year follow-up. Clin Exp Ophthalmol. 2014 Apr;42(3):235-41. doi: 10.1111/ceo.12140. Epub 2013 Jul 5.</citation>
    <PMID>23777441</PMID>
  </results_reference>
  <results_reference>
    <citation>Hu Q, Qiao Y, Nie X, Cheng X, Ma Y. Bevacizumab in the treatment of pterygium: a meta-analysis. Cornea. 2014 Feb;33(2):154-60. doi: 10.1097/ICO.0000000000000037.</citation>
    <PMID>24326333</PMID>
  </results_reference>
  <results_reference>
    <citation>Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008 Jan;33(1):23-8. doi: 10.1080/02713680701799101.</citation>
    <PMID>18214740</PMID>
  </results_reference>
  <results_reference>
    <citation>Bayar SA, Kucukerdonmez C, Oner O, Akova YA. Subconjunctival bevacizumab in the impending recurrent pterygia. Int Ophthalmol. 2014 Jun;34(3):541-7. doi: 10.1007/s10792-013-9852-1. Epub 2013 Sep 12.</citation>
    <PMID>24026871</PMID>
  </results_reference>
  <results_reference>
    <citation>Fallah Tafti MR, Khosravifard K, Mohammadpour M, Hashemian MN, Kiarudi MY. Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Cornea. 2011 Feb;30(2):127-9. doi: 10.1097/ICO.0b013e3181e16d67.</citation>
    <PMID>20885313</PMID>
  </results_reference>
  <results_reference>
    <citation>Besharati MR, Manaviat MR, Souzani A. Subconjunctival bevacizumab injection in treatment of pterygium. Acta Med Iran. 2011;49(3):179-83.</citation>
    <PMID>21681707</PMID>
  </results_reference>
  <results_reference>
    <citation>Sarac O, Demirel S, Oltulu R. Efficacy of intralesional bevacizumab administration in primary pterygium: a quantitative analysis. Eye Contact Lens. 2014 Jan;40(1):46-50. doi: 10.1097/ICL.0000000000000004.</citation>
    <PMID>24335454</PMID>
  </results_reference>
  <results_reference>
    <citation>Kocabora SM, Fazil K, Ozsutcu M, Doyduk-Kocabora A, Gulkilik G. Subconjunctival bevacizumab injection in the surgery of primary pterygium: comparison with intraoperative mitomycin-C. Bull Soc Belge Ophtalmol. 2013;(322):7-12.</citation>
    <PMID>24923076</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>January 14, 2015</last_update_submitted>
  <last_update_submitted_qc>January 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Science Malaysia</investigator_affiliation>
    <investigator_full_name>Hao Chi Ho</investigator_full_name>
    <investigator_title>DR.</investigator_title>
  </responsible_party>
  <keyword>pterygium</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>anti-VEGF</keyword>
  <keyword>recurrence</keyword>
  <keyword>vascularity</keyword>
  <keyword>size</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

